Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
3.620
-0.180 (-4.74%)
At close: Apr 28, 2026, 4:00 PM EDT
3.600
-0.020 (-0.55%)
After-hours: Apr 28, 2026, 6:38 PM EDT
LIXT Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
3
Market Cap
42.06M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 120.77M |
| Palatin Technologies | 8.96M |
| Plus Therapeutics | 5.21M |
| Nutriband | 2.28M |
| Rallybio | 858.00K |
| Mereo BioPharma Group | 500.00K |
LIXT News
- 15 days ago - Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference - GlobeNewsWire
- 4 weeks ago - LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year - GlobeNewsWire
- 2 months ago - LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary - GlobeNewsWire
- 3 months ago - DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE - GlobeNewsWire
- 3 months ago - LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29 - GlobeNewsWire
- 4 months ago - LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial - GlobeNewsWire
- 5 months ago - LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities - Accesswire
- 5 months ago - LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology - Accesswire